{"doi":"10.3109/07357907.2010.483506","title":"Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling","abstract":null,"journal":"Cancer Investigation","year":2010,"id":597714,"datarank":0.48283137373023016,"base_score":3.2188758248682006,"endowment":3.2188758248682006,"self_citation_contribution":0.48283137373023016,"citation_network_contribution":0.0,"self_endowment_contribution":0.48283137373023016,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":24,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":226643,"name":"Ulrik Lassen","orcid":"0000-0002-3865-4574","position":1,"is_corresponding":false},{"id":1531341,"name":"Hans S. Poulsen","orcid":null,"position":2,"is_corresponding":false},{"id":1531342,"name":"Marie-Thérése Stockhausen","orcid":null,"position":3,"is_corresponding":false},{"id":1531340,"name":"Benedikte Hasselbalch","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling","abstract":"Overexpression and/or amplification of the epidermal growth factor receptor (EGFR) is present in 35-45% of primary glioblastoma multiforme tumors and has been correlated with a poor prognosis. In this study, we investigated the effect of cetuximab and intracellular signaling pathways downstream of EGFR, important for cell survival and proliferation. We show insufficient EGFR downregulation and competition with endogenous EGFR ligands upon cetuximab treatment. Dose-response experiments showed inhibition of EGFR phosphorylation without affecting two of the prominent downstream signaling pathways. Our results indicate that amplification and/or overexpression of EGFR is an unsatisfactory predictor for response to cetuximab.","is_dataset_classified":null,"base_score":3.2188758248682006,"endowment":3.2188758248682006,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"20504227","pmcid":null,"openalex_id":"https://openalex.org/W2147881050","authors":[],"funders":[],"total_grants":0,"fwci":1.8045,"citation_percentile":0.85354736,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":5},{"year":2014,"count":2},{"year":2015,"count":3},{"year":2019,"count":2},{"year":2020,"count":1},{"year":2021,"count":1},{"year":2022,"count":1},{"year":2024,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.tandfonline.com/doi/pdf/10.3109/07357907.2010.483506","host_type":"publisher"},{"url":"https://doi.org/10.3109/07357907.2010.483506","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/20504227","host_type":"repository"},{"url":"https://researchprofiles.ku.dk/da/publications/3b4e94b9-9918-4bc4-9d2b-d80a051ced11","host_type":"repository"}],"fields_of_study":["HER2/EGFR in Cancer Research","Glioma Diagnosis and Treatment","Protein Degradation and Inhibitors","Antibodies, Monoclonal","Antibodies, Monoclonal, Humanized","Antineoplastic Agents","Carcinoma, Squamous Cell","Cell Division","Cell Line, Tumor","Cell Survival","Cetuximab","Cycloheximide","Drug Resistance, Neoplasm","Epidermal Growth Factor","ErbB Receptors","Flow Cytometry","Gene Amplification","Gene Expression Regulation, Neoplastic","Glioma","Head and Neck Neoplasms","Humans","Phosphorylation","Signal Transduction"],"mesh_terms":["Cetuximab","Antibodies, Monoclonal","Antineoplastic Agents","Carcinoma, Squamous Cell","Cell Division","Cell Survival","Cycloheximide","Epidermal Growth Factor","Flow Cytometry","Gene Amplification","Glioma","Head and Neck Neoplasms","Humans","Phosphorylation","Signal Transduction","Gene Expression Regulation, Neoplastic","Drug Resistance, Neoplasm","Cell Line, Tumor","Antibodies, Monoclonal, Humanized","ErbB Receptors"],"keywords":["Cetuximab","Epidermal growth factor receptor","Downregulation and upregulation","EGFR inhibitors","Cancer research","Signal transduction","Phosphorylation","Cell growth","Glioma","Receptor","Chemistry","Biology","Medicine","Internal medicine","Cancer","Cell biology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"No poverty"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T14:01:39.460063Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}